Latest Gastrointestinal cancer Stories

SAN FRANCISCO, June 28, 2012 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic immunotherapy products for cancer, today announced that Laurent Fischer, M.D., has been appointed to the positions of president, chief executive officer and board member. He succeeds interim CEO, Ken Newport, who will continue in his role as a board member of the company. Dr. Fischer brings...

Comprehensive strategy includes more accurate CT scan analysis, complex surgical technique Investigators at the University of Texas MD Anderson Cancer Center, Houston, have reported on a new approach to treating previously inoperable complex pancreatic adenocarcinoma that has significantly increased long-term survival for some patients. Pancreatic adenocarcinoma is one of the most devastating forms of pancreatic cancer with survival rates of only 5 percent at five years. Surgical removal...

MELBOURNE, Australia, June 26, 2012 /PRNewswire/ -- Circadian Technologies Limited (ASX: CIR, OTCQX: CKDXY) announces that it has been advised by its development partner, Healthscope Advanced Pathology, that it will commercially launch Circadian's novel technology for aid in the diagnosis of "Cancers of Unknown Primary" (CUP), on Monday July 16 2012 in Australia, New Zealand, Singapore and Malaysia under the brand CUPGUIDE(TM). The diagnostic test method has been developed in...

WASHINGTON, June 26, 2012 /PRNewswire/ -- Sterne, Kessler, Goldstein & Fox P.L.L.C., an intellectual property law firm in Washington, DC, has been selected to represent Jack Andraka as he pursues patent protection for an innovative diagnostic test for pancreatic cancer. Last month, the fifteen year old was honored with the first place prize at the Intel International Science and Engineering Fair. After a family friend died from pancreatic cancer, Mr. Andraka was inspired to...

(Ivanhoe Newswire) – There are more than 42 thousand new diagnosed cases of pancreatic cancer in the U.S., and of those, more than 35 thousand have resulted in death. Now researchers are looking at a new treatment that could change how we view pancreatic cancer. A novel chemotherapeutic agent, the highly selective MEK1/2 inhibitor BAY 86-9766, may be a promising future treatment for pancreatic ductal adenocarcinoma (PDAC). In a preclinical therapeutic study, BAY 86-9766 was evaluated in...

MANHATTAN BEACH, Calif., June 21, 2012 /PRNewswire/ -- The U.S. House Committee on Energy & Commerce today held a hearing at which the Pancreatic Cancer Research & Education Act (S. 362/H.R. 733) was discussed. The bill would require the National Cancer Institute (NCI) to develop a long-term comprehensive strategic research plan that would help develop early diagnostics and effective treatment options for patients that would increase survival rates for pancreatic cancer....

HASLEMERE, England, June 21, 2012 /PRNewswire/ -- The Pancreatic Cancer activists congregate over Twitter to provide an exclusive question and answer session - all about pancreatic cancer This Friday 22 June 2012, Pancreatic Cancer Action are hosting a special and unique event. Taking to the Twitter-o-sphere, the cancer experts are providing an extraordinary question and answer session that is open to the wider Twitter populous. Coined, Let's Talk...

Severe pain is a major symptom of pancreatic cancer. The results of a new study show that four different factors involved in the growth and maintenance of nerves are elevated in a mouse model of pancreatic cancer. This is a step forward in understanding the relationship between the development of pain and the progression of pancreatic cancer. "When other researchers have looked at samples of pancreatic cancer, they have described perineural tumor invasion in as many as 90 to 100 percent of...

Combining a new targeted therapy with standard chemotherapy may help defeat pancreatic cancer, according to results presented at the American Association for Cancer Research's Pancreatic Cancer: Progress and Challenges conference, held here June 18-21. "We believe that GDC-0449 has the potential to change the approach to treating pancreatic cancer," said Edward J. Kim, M.D., Ph.D., a medical oncologist at the University of Michigan Comprehensive Cancer Center in Ann Arbor, Mich....

Researchers at the City of Hope Comprehensive Cancer Center have not only identified a protein that allows pancreatic cancer cells to resist therapy but also developed a way to block it, according to results presented at the American Association for Cancer Research's Pancreatic Cancer: Progress and Challenges conference, held here June 18-21. "Cancer of the pancreas is notoriously difficult to treat because it usually presents at late stages due to minimal or nonspecific symptoms in the...